In addition, the company enjoyed higher revenue from Wuxi Lippo Xi Nan hospital and its drug distribution business in China, led by higher demand for pandemic-related medical supplies.
OUE Lippo Healthcare has reported earnings of $32.5 million for FY2022, versus earnings of $110.9 million reported for the preceding financial year ended Dec 31 2021. The higher numbers for FY2021 were largely because of one-off gains.
Revenue for FY2022 reached $119.8 million, versus just $19.7 million in FY2021, as the company began to consolidate numbers from First REIT from last year March from its medical partners from last July respectively.
